Ceftriaxone

Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC₅₀ value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis^{[1][2][3][4][5][6][7]}. IC50 & Target:IC50: 0.78 mM (GSK3β)^[2] In Vitro:Ceftriaxone (100 μM, 24 h) protects MPP⁺ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway ^[3].
Ceftriaxone (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B^[4].
In Vivo:Ceftriaxone (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury^[5].
Ceftriaxone (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats^[6].
Ceftriaxone (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in Streptozocin (HY-13753)-induced diabetic rat models^[7].